Skip to main content

Advertisement

SpringerLink
Log in

Urinary pentosidine level is associated with the risk of fracture in community-dwelling older adults: a prospective observational study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

A history of fracture in adulthood and urinary pentosidine levels were independently and significantly associated with fracture occurrence in this prospective observational study of community-dwelling older adults.

Purpose

This prospective observational study aimed to determine the factors associated with fragility fractures in community-dwelling older adults.

Methods

Overall, 254 older adults who were participants of the Good Aging and Intervention Against Nursing Care and Activity Decline study in 2016 were included in this study. Grip strength, muscle mass, gait speed, calcaneal bone density, and the levels of parathyroid hormone, osteocalcin, 25-hydroxyvitamin D, total procollagen type I N-terminal propeptide, insulin-like growth factor-1 (IGF-1), tartrate-resistant acid phosphatase-5b, and urinary pentosidine were measured at baseline. Participants were classified as fracture ( +) or fracture (-) based on the data collected during a 5-year follow-up period.

Results

Excluding those who were lost to follow-up during the observation period, 182 participants (64 men and 118 women, mean age: 74.2 years, range: 47–99 years) were included in the analysis. During the observation period, 23 patients experienced 24 new fractures. In univariate analysis, sex, height, weight, history of fracture in adulthood, baseline grip strength, muscle mass, bone density, and the levels of urinary pentosidine and IGF-1 at baseline were significantly different between patients who developed a fracture during follow-up and those who did not. In multivariate analysis, a history of fracture in adulthood and urinary pentosidine levels were independently and significantly associated with fracture occurrence.

Conclusion

High urine pentosidine levels and a history of fracture in adulthood are independent risk factors for fracture occurrence in community-dwelling older adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The datasets analyzed in this study are not publicly available because they are part of private records. However, upon appropriate request, they are available from the corresponding author as de-identified datasets.

References

  1. NIH Consensus Development Panel on Osteoporosis Prevention DaT (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

    Article  Google Scholar 

  2. Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, Kanis JA (2017) Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD Cohort. J Bone Miner Res 32:1568–1574

    Article  PubMed  Google Scholar 

  3. Cheung WH, Hung VW, Cheuk KY et al (2021) Best performance parameters of HR-pQCT to predict fragility fracture: systematic review and meta-analysis. J Bone Miner Res 36:2381–2398

    Article  PubMed  Google Scholar 

  4. Saito M, Marumo K (2015) Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int 97:242–261

    Article  CAS  PubMed  Google Scholar 

  5. Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195–214

    Article  CAS  PubMed  Google Scholar 

  6. Kashiwabara S, Hosoe H, Ohno R, Nagai R, Shiraki M (2019) Development and evaluation of novel ELISA for determination of urinary pentosidine. J Nutr Sci Vitaminol 65:526–533

    Article  CAS  PubMed  Google Scholar 

  7. Moriwaki K, Matsumoto H, Tanimura C, Osaki M, Nagashima H, Hagino H (2021) Urinary pentosidine level is associated with grip strength and gait speed in community-dwelling adults: a cross-sectional study. BMC Musculoskelet Disord 22:392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moriwaki K, Matsumoto H, Tanishima S, Tanimura C, Osaki M, Nagashima H, Hagino H (2019) Association of serum bone- and muscle-derived factors with age, sex, body composition, and physical function in community-dwelling middle-aged and elderly adults: a cross-sectional study. BMC Musculoskelet Disord 20:276

    Article  PubMed  PubMed Central  Google Scholar 

  9. Matsumoto H, Tanimura C, Kushida D, Osaka H, Kawabata Y, Hagino H (2020) FRAX score and recent fall history predict the incidence for sarcopenia in community-dwelling older adults: a prospective cohort study. Osteoporos Int 31:1985–1994

    Article  CAS  PubMed  Google Scholar 

  10. Matsumoto H, Hagino H, Sageshima H, Osaki M, Tanishima SCT (2015) Diagnosis of knee osteoarthritis and gait variability increases risk of falling for osteoporotic older adults: The GAINA study. Osteoporos Sarcopenia 1:46–52

  11. Subramaniam S, Chan CY, Soelaiman IN, Mohamed N, Muhammad N, Ahmad F, Ng PY, Jamil NA, Aziz NA, Chin KY (2020) The performance of a calcaneal quantitative ultrasound device, CM-200, in stratifying osteoporosis risk among Malaysian population aged 40 years and above. Diagnostics (Basel) 10:178

    Article  PubMed  Google Scholar 

  12. Shiraki M, Kashiwabara S, Imai T, Tanaka S, Saito M (2019) The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women. J Bone Miner Metab 37:1067–1074

    Article  CAS  PubMed  Google Scholar 

  13. Tamaki J, Kouda K, Fujita Y, Iki M, Yura A, Miura M, Sato Y, Okamoto N, Kurumatani N (2018) Ratio of endogenous secretory receptor for advanced glycation end products to pentosidine predicts fractures in men. J Clin Endocrinol Metab 103:85–94

    Article  PubMed  Google Scholar 

  14. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nakano M, Kubota M, Owada S, Nagai R (2013) The pentosidine concentration in human blood specimens is affected by heating. Amino Acids 44:1451–1456

    Article  CAS  PubMed  Google Scholar 

  16. Tanaka S, Kuroda T, Saito M, Shiraki M (2011) Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women. J Bone Miner Res 26:2778–2784

    Article  CAS  PubMed  Google Scholar 

  17. Gineyts E, Munoz F, Bertholon C, Sornay-Rendu E, Chapurlat R (2010) Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int 21:243–250

    Article  CAS  PubMed  Google Scholar 

  18. Hagino H, Uemura Y, Mori S, Sone T, Ohta H, Nakamura T (2021) Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study. J Bone Miner Metab 39:668–677

    Article  CAS  PubMed  Google Scholar 

  19. Tanaka S, Saito M, Hagino H et al (2022) Association of urinary pentosidine levels with the risk of fractures in patients with severe osteoporosis: the Japanese Osteoporosis Intervention Trial-05 ( JOINT-05). JBMR Plus 6:e10673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors sincerely acknowledge the town of Hino in the Tottori Prefecture, Japan. The authors also thank all staff members involved in the Good Aging and Intervention Against Nursing Care and Activity Decline (GAINA) study.

Funding

This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Scientific Research and by funding from the School of Health Sciences, Faculty of Medicine, Tottori University, and JSPS KAKENHI Grant Number JP19K11809. The funders were not involved in the design, data collection, analysis, interpretation, or writing of this manuscript.

Author information

Authors and Affiliations

  1. School of Health Science, Faculty of Medicine, Tottori University, Nishicho 86, Yonago, Tottori, 683-8503, Japan

    Hiroshi Hagino

  2. Department of Rehabilitation, Sanin Rosai Hospital, 1-8-1 Kaikeshinden, Yonago, Tottori, 683-8605, Japan

    Hiroshi Hagino

  3. Department of Orthopedic Surgery, Faculty of Medicine, Tottori University, Nishicho 36-1, Yonago, Tottori, 683-8504, Japan

    Kenta Moriwaki & Hideki Nagashima

  4. Rehabilitation Division, Tottori University Hospital, Nishicho 36-1, Yonago, Tottori, 683-8504, Japan

    Takashi Wada & Mari Osaki

  5. Department of Physical Therapy, Faculty of Rehabilitation, Kawasaki University of Medical Welfare, Matsushima 288, Kurashiki, Okayama, 701-0193, Japan

    Hiromi Matsumoto

Authors
  1. Hiroshi Hagino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenta Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mari Osaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideki Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiromi Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Hagino.

Ethics declarations

Conflict of interest

HH received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. HN received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Johnson & Johnson K.K., Kyocera Corp., Medtronic, NuVasive Inc., Nippon Zoki Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teijin Nakashima Medical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.

KM, TW, MO, and HM declare that they have no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hagino, H., Moriwaki, K., Wada, T. et al. Urinary pentosidine level is associated with the risk of fracture in community-dwelling older adults: a prospective observational study. Osteoporos Int 34, 1703–1709 (2023). https://doi.org/10.1007/s00198-023-06816-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-023-06816-5

Keywords

Search

Navigation